top of page
Leading the Way in Intratumoral Radiotherapeutics
News​
Categories
Sign up
Featured Posts
Archive
Follow Us
Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRTâ„¢
JERUSALEM, June 22, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer...
Jun 23, 2022
Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site
Alpha Tau Announces Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site, Amended...
Jun 16, 2022
FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRTâ„¢ in Recurrent Cutaneous SCC
JERUSALEM, June 8, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the "Company"), the developer of the...
Jun 8, 2022
Alpha Tau Announces Resignation of Gary Leibler from its Board of Directors
JERUSALEM, June 7, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the...
Jun 8, 2022
bottom of page